ImmunityBio
ImmunityBio is a life sciences company that focuses on immunotherapy and leveraging the body’s Natural Killer cells to enhance the immune system’s response to cancer and chemotherapy.
History[edit]
ImmunityBio was founded in 2014 by Dr. Patrick Soon-Shiong.[1]
In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.[2][3]
On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund trials involving non-human primates.[4] The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."[4]
ImmunityBio is developing several vaccine candidates against COVID-19. Their vaccines are under Phase I, II, III stage in various countries.
- Adenovirus Type 5 + DNA (hAd5)
- Nanostructured lipid carriers (NLCs) + RNA (saRNA)[5]
- Yeast + RBD + Adjuvants[6]
References[edit]
- ↑ "Oral COVID-19 vaccine being tested in Los Angeles-area research center". www.cbsnews.com. Retrieved 2021-04-14.
- ↑ "NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter". BioSpace.com. 14 April 2020.
- ↑ Cross, Ryan (12 May 2020). "Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?". Chemical & Engineering News. 98 (19).
- ↑ 4.0 4.1 Cohen, Jon (1 June 2020). "Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests". American Association for the Advancement of Science. Science (magazine).
- ↑ "Preclinical data shows enhanced T-cell responses & neutralization of SARS-CoV-2 variants with ImmunityBio heterologous vaccination". News-Medical.net. 2021-12-05. Retrieved 2022-02-19.
- ↑ "ImmunityBio S4 Filing". 2021.
This article "ImmunityBio" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:ImmunityBio. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
